A5012310765- Ovarian cancer diagnosis and treatment
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- BRCA gene mutations in cancer
- PARP inhibition in cancer therapy
- Genetic factors in colorectal cancer
- Women's cancer prevention and management
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Colorectal and Anal Carcinomas
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Oral health in cancer treatment
- Gastrointestinal Tumor Research and Treatment
- Medicinal Plant Research
- Cancer Diagnosis and Treatment
- Genomics, phytochemicals, and oxidative stress
- Cancer Mechanisms and Therapy
- Global Cancer Incidence and Screening
- Mobile Health and mHealth Applications
- COVID-19 and healthcare impacts
- Gastrointestinal disorders and treatments
Centro Medico Nacional Siglo XXI
2009-2024
Mexican Social Security Institute
2011-2024
Centro Médico ABC
2021
Centro Médico Nacional La Raza
2014-2018
Hospital General de México
2011
PURPOSE A phase II study (ClinicalTrials.gov identifier: NCT00628251 ) showed activity of olaparib capsules versus pegylated liposomal doxorubicin in patients with germline BRCA-mutated platinum-resistant or partially platinum-sensitive relapsed ovarian cancer. We conducted a III trial (SOLO3) tablets nonplatinum chemotherapy cancer who had received at least 2 prior lines platinum-based chemotherapy. PATIENTS AND METHODS In this randomized, open-label trial, were randomly assigned 2:1 to 300...
•Data on outcomes in patients with rapidly relapsing TNBC are scarce.•The phase III IMpassion132 trial enrolled relapse <12 months after chemotherapy/surgery for early TNBC.•OS was not improved by adding atezolizumab to chemotherapy PD-L1-positive TNBC.•Patients have a dismal prognosis and represent population huge unmet need. BackgroundImmune checkpoint inhibitors improve the efficacy of first-line programmed death-ligand 1 (PD-L1)-positive unresectable locally advanced/metastatic...
We assessed the treatment effect of panitumumab plus best supportive care (BSC) vs BSC on overall survival (OS) in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) and report first prospective extended RAS analysis a phase 3 trial. Patients mCRC were randomised 1 : to (6 mg kg−1 Q2W) or BSC. On-study crossover was prohibited. mutation status determined by central laboratory testing. The primary endpoint OS mCRC; (KRAS NRAS exons 2, 3, 4) secondary...
Immune checkpoint inhibitors (ICIs) improve efficacy of first-line CT for some patients (pts) with aTNBC but data in early relapse are limited. IMpassion132 (NCT03371017) enrolled pts relapsing <12 mo after the last any anthracycline- and taxane-containing (neo)adjuvant or primary TNBC surgery. PD-L1 status was centrally assessed by SP142 before randomisation. Initially were irrespective status. In Aug 2019 protocol amended to enrich PD-L1+ (tumour immune cell ≥1%) aTNBC. Stratification...
5506 Background: Data from a randomized Phase II trial (NCT00628251) of olaparib (capsules, 200 or 400 mg bid, n=32 per arm) vs pegylated liposomal doxorubicin (PLD, n=33) in gBRCAm OC pts with recurrence ≤12 months after prior platinum therapy indicated efficacy for (Kaye et al. JCO 2012). However, the PLD was higher than previously reported this setting. We led confirmatory III, open-label study non-platinum chemotherapy PSR (NCT02282020). Methods: Pts were (2:1) to tablets (300 bid)...
The article discusses the importance of accurately distinguishing HER2-low from HER2-negative breast cancer, as novel ADCs have demonstrated activity in a large population patients with HER2-low-expressing BC. While current guidelines recommend dichotomous classification HER2 either positive or negative, emergence concept calls for standardization testing using currently available assays to better discriminate levels. This review covers evolution and latest updates ASCO/CAP relevant this...
Human papillomavirus (HPV) infection is a well-known cause of cervical cancer. Therapeutic cancer vaccines are part the current therapeutic options for HPV-associated cancers. Axalimogen filolisbac (ADXS11-001) an immunotherapy based on live attenuated Listeria monocytogenes-listeriolysin O (Lm-LLO), designed by biological engineering to secrete antigen-adjuvant fusion protein, composed truncated fragment LLO fused HPV. The proposed mechanism action that Lm-based vectors infect...
IntroductionTumor rat sarcoma gene (RAS) status is a negative predictive biomarker for anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). We analyzed outcomes according to RAS and v-Raf murine viral oncogene homolog B (BRAF) mutational status, evaluated early tumor shrinkage (ETS) depth of response (DpR) patients with wild type RAS.Patients MethodsPatients confirmed colon or rectum adenocarcinoma, Kristen exon 2 clinical/radiologic disease...
Olaparib treatment significantly improved objective response rate (primary end point) and progression-free survival versus nonplatinum chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer the open-label phase III SOLO3 trial (ClinicalTrials.gov identifier: NCT02282020 ). We report final overall (OS; prespecified secondary point), post hoc OS analysis by number of previous lines, exploratory BRCA reversion mutation analysis. Two hundred sixty-six were randomly...
Generating a consensus in the Latin-American region on cancer pain management is current need. Thus panel of experts met Madrid March 2017 order to review published literature, discuss best approach for classification and evaluation also make recommendations pharmacological nonpharmacological therapies improvement countries. The result that meeting presented this document. participating were from Costa Rica, Mexico, Chile, Colombia, Peru, Brazil Ecuador, project coordinator was Spain.
Background/Aim: Non-small-cell lung cancer (NSCLC) is the most frequently diagnosed malignancy and first cause of cancer-related death. Thus, finding alternative therapeutic options crucial. Drug repurposing offers in a simplified affordable manner, especially to patients developing countries. Several drugs including antihistamines beta-adrenergic receptor blockers (beta-blockers) display antiproliferative properties on cells. Interestingly, NSCLC who had used either or beta-blockers showed...
Objectives This study aimed to explore the acceptability, feasibility, usability, and preliminary effect of an electronic patient-reported outcome (ePRO) intervention for patients with breast cancer in Mexico. Design We conducted a multimethod non-randomised pilot study. used pre-test/post-test design quantitative assessment intervention’s on patients’ supportive care needs quality life. in-depth interviews (IDIs) participants healthcare workers benefits barriers understand its feasibility....
642 Background: An overall survival (OS) benefit in WT KRAS exon 2 mCRC was not seen with pmab monotherapy study 20020408 possibly due to crossover of patients (pts) the BSC arm. Retrospective analyses have indicated that other and NRAS mutations beyond are predictive anti-EGFR tx effects. Study 20100007 assesses OS chemorefractory is first phase 3 trial prospectively evaluate effects RAS (exons 2, 3, 4 NRAS) mCRC. Methods: Anti-EGFR naive pts were randomized 1:1 receive (6 mg/kg Q2W) + or...
3536 Background: In the primary analysis of study 20100007, pmab + BSC significantly improved OS and PFS vs in WT KRAS exon 2 mCRC and, first prospective phase 3 study, RAS (exons 2, 3, 4 NRAS) mCRC. We report final evaluate BRAF status from 20100007. Methods: Anti-EGFR naïve patients (pts) with were randomized 1:1 to or BSC. On-study crossover was prohibited. assessed centrally. The endpoint mCRC; secondary endpoints safety both populations. Pts followed for survival ≥2 years after last pt...
Colorectal cancer is one of the most common cancers worldwide, and although associated mortality rates in South American countries are generally among lowest world, they on rise. The prognosis patients diagnosed with metastatic colorectal has improved markedly over last 12 years, increasing from 5 months best supportive care to almost 2 years combination chemotherapy plus bevacizumab. New prognostic predictive biomarkers have been identified guide therapy. Prognostic markers indicate patient...
e15144 Background: To analyze overall survival, free disease complete and partial pathologic response, effect of stage reduction, toxicity profile number anus preservative surgery in patients treated with concurrent chemo radiotherapy a modified 5-FU single agent regimen as neoadjuvant modality treatment. Methods: Historic Cohort the Oncology Hospital, CMNSXXI between January 1999 to December 2004. The scheme used was bolus 5FU 425mg/m2 without leocovorin three consecutive days each two...